Gibson Oncology, NIH to begin Phase 2 trials of LMP744 for treatment of first-time recurrent glioblastoma
February 25, 2026
February 25, 2026
WEST LAFAYETTE, Indiana, Feb. 25 -- Purdue University issued the following news release:
* * *
Gibson Oncology, NIH to begin Phase 2 trials of LMP744 for treatment of first-time recurrent glioblastoma
*
WEST LAFAYETTE, Ind. and MIAMI - Gibson Oncology, a clinical-stage private pharmaceutical company headquartered in Miami, announced it has entered Phase 2 clinical trials with LMP744 for the treatment of first-time recurrent glioblastoma patient . . .
* * *
Gibson Oncology, NIH to begin Phase 2 trials of LMP744 for treatment of first-time recurrent glioblastoma
*
WEST LAFAYETTE, Ind. and MIAMI - Gibson Oncology, a clinical-stage private pharmaceutical company headquartered in Miami, announced it has entered Phase 2 clinical trials with LMP744 for the treatment of first-time recurrent glioblastoma patient . . .